BELLUS Health
Market Cap
CA$402.7m
Last Updated
2021/01/20 00:25 UTC
Data Sources
Company Financials +
Executive Summary
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 10.1% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has BELLUS Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BLU is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: BLU's weekly volatility has decreased from 16% to 11% over the past year.
Market Performance
7 Day Return
16.3%
BLU
10.7%
CA Biotechs
0.2%
CA Market
1 Year Return
-54.2%
BLU
32.3%
CA Biotechs
1.5%
CA Market
Return vs Industry: BLU underperformed the Canadian Biotechs industry which returned 32.3% over the past year.
Return vs Market: BLU underperformed the Canadian Market which returned 1.5% over the past year.
Shareholder returns
| BLU | Industry | Market | |
|---|---|---|---|
| 7 Day | 16.3% | 10.7% | 0.2% |
| 30 Day | 33.8% | 31.4% | 3.6% |
| 90 Day | 58.9% | 23.6% | 13.3% |
| 1 Year | -54.2%-54.2% | 32.3%32.3% | 5.2%1.5% |
| 3 Year | 247.7%247.7% | 17.4%17.4% | 13.1%2.3% |
| 5 Year | 32.9%32.9% | 35.8%35.8% | 69.3%43.3% |
Long-Term Price Volatility Vs. Market
How volatile is BELLUS Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
How Many BELLUS Health Inc. (TSE:BLU) Shares Do Institutions Own?2 months ago | Simply Wall St
Roberto Bellini Is The President of BELLUS Health Inc. (TSE:BLU) And They Just Picked Up 7.2% More Shares3 months ago | Simply Wall St
Is BELLUS Health (TSE:BLU) In A Good Position To Invest In Growth?Valuation
Is BELLUS Health undervalued compared to its fair value and its price relative to the market?
2.08x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BLU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BLU is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: BLU is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLU is good value based on its PB Ratio (2.1x) compared to the CA Biotechs industry average (6.8x).
Next Steps
Future Growth
How is BELLUS Health forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
-10.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLU's revenue (88.5% per year) is forecast to grow faster than the Canadian market (7.9% per year).
High Growth Revenue: BLU's revenue (88.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLU is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has BELLUS Health performed over the past 5 years?
-73.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLU is currently unprofitable.
Growing Profit Margin: BLU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLU is unprofitable, and losses have increased over the past 5 years at a rate of 73.6% per year.
Accelerating Growth: Unable to compare BLU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: BLU has a negative Return on Equity (-29.42%), as it is currently unprofitable.
Next Steps
Financial Health
How is BELLUS Health's financial position?
Financial Position Analysis
Short Term Liabilities: BLU's short term assets ($71.6M) exceed its short term liabilities ($6.2M).
Long Term Liabilities: BLU's short term assets ($71.6M) exceed its long term liabilities ($375.0K).
Debt to Equity History and Analysis
Debt Level: BLU is debt free.
Reducing Debt: BLU had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BLU has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 48.8% each year.
Next Steps
Dividend
What is BELLUS Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLU's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.9yrs
Average management tenure
CEO
Roberto Bellini (40 yo)
11yrs
Tenure
US$1,715,877
Compensation
Mr. Roberto Bellini has been the Chief Executive Officer and President of BELLUS Health Inc, since January 1, 2010. Mr. Bellini served as an Executive Vice President of Picchio Pharma Inc. until January 1,...
CEO Compensation Analysis
Compensation vs Market: Roberto's total compensation ($USD1.72M) is above average for companies of similar size in the Canadian market ($USD789.12K).
Compensation vs Earnings: Roberto's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11yrs | US$1.72m | 0.80% $ 3.2m | |
| Vice President of Finance | 11.5yrs | US$450.86k | 0.011% $ 42.8k | |
| Senior Vice President of Drug Development | 16yrs | US$643.11k | 0.00086% $ 3.5k | |
| Chief Medical Officer | 1.42yrs | US$2.72m | no data | |
| Vice President of Business Development | 8.92yrs | US$475.86k | no data | |
| Chief Financial Officer | 0.083yr | no data | no data | |
| Director of Investor Relations & Communications | no data | no data | no data | |
| Corporate Secretary | 9.92yrs | no data | 0.0021% $ 8.3k |
9.9yrs
Average Tenure
47yo
Average Age
Experienced Management: BLU's management team is seasoned and experienced (9.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11yrs | US$1.72m | 0.80% $ 3.2m | |
| Chairman of the Board | no data | US$353.48k | 0.54% $ 2.2m | |
| Independent Director | 10.67yrs | US$120.84k | 0.67% $ 2.7m | |
| Independent Director | 11.58yrs | US$130.48k | no data | |
| Independent Director | 3.33yrs | US$115.06k | 0.024% $ 94.7k | |
| Independent Director | 3.67yrs | US$120.84k | 0.14% $ 563.6k | |
| Independent Lead Director | no data | US$155.54k | 0.17% $ 676.3k | |
| Member of Clinical Advisory Board | 2.33yrs | no data | no data | |
| Chairman of the Clinical Advisory Board | 2.33yrs | no data | no data | |
| Member of Clinical Advisory Board | 2.33yrs | no data | no data | |
| Member of Clinical Advisory Board | 2.33yrs | no data | no data | |
| Member of Clinical Advisory Board | 2.33yrs | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Board: BLU's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BLU insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.5%.
Top Shareholders
Company Information
BELLUS Health Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: BELLUS Health Inc.
- Ticker: BLU
- Exchange: TSX
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$402.654m
- Shares outstanding: 78.34m
- Website: https://www.bellushealth.com
Number of Employees
Location
- BELLUS Health Inc.
- 275 Armand-Frappier Boulevard
- Laval
- Quebec
- H7V 4A7
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BHN0 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jun 2000 |
| BLU | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Jun 2000 |
| BLU | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Jun 2000 |
| 0A4U | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Jun 2000 |
Biography
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/20 00:25 |
| End of Day Share Price | 2021/01/19 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.